Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology

Abstract

Introduction: Nuclear factor kappa B/p65 (NF-kB/p65) regulates expression of molecules important in tumorigenesis as cyclooxygenase-2 (COX-2).Aim: To study the immunohistochemical expression of NF-kB/p65 and COX-2 in NSCLC, investigate the relationship between their expression and clinicopathological parameters, evaluate their prognostic value and impact on survival.Patients and Methods: 50 NSCLC patients were enrolled in this study and subjected to: medical history, physical examination, laboratory tests and CT chest. Fiberoptic bronchoscopy was done; biopsies were taken from visible masses and 20 mucosal biopsies as control; sent for immunohistochemical examination using anti-COX2 and anti-NF-kB/p65 antibodies.The median follow up of patients was 13 (range 4-22 months).Results: 36 (72%) showed positive NF-kB/p65 expression, it was higher in squamous cell carcinoma and adenocarcinoma than in normal biopsies. Adenocarcinoma showed higher NF-kB/p65 positivity compared to squamous and large cell carcinomas with significant relationship between NF-kB/p65 expression and overall survival.45 (90%) showed positive COX-2 expression, no expression in normal biopsies. COX-2 expression was significantly higher in adenocarcinoma compared to squamous and large cell carcinomas. NF-kB/p65 and COX-2 expression was significantly correlated with advanced tumor stage, lymph node metastasis and grade. Significant positive relationship was found between NF-kB/p65 and COX-2 expression.Conclusions: NF-kB/P65 and COX-2 expression has a prognostic value in NSCLC, inhibition of NF-kB and COX-2 will augment the efficacy of anticancer therapy.

Rating:

Share or cite this content

Citations should be made in the following way:
G. H. Abo El-Magd, O. Abd El-Fattah, E. M. Saied (Tanta, Egypt). Immunohistochemical expression of nuclear factor kappa-B/p65 and cyclooxygenase-2 in non-small cell lung cancer patients: Prognostic value and impact on survival. Eur Respir J 2014; 44: Suppl. 58, 512

Member's Comments

No comment yet.

Related content which might interest you: beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Rhesus CE expression is an independent prognostic factor in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Prognostic value study of lung cancer molecular markers and value of mitochondrial activity in resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015 Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Epidermal growth factor receptor and related biomarkers evaluated by immunohistochemistry in patients with resected non-small cell lung cancer Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 CD33+CD14-CD11b+CD66b+CD15+VEGFR-1hi myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Expression analysis of miR-21 in Bulgarian patients with non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers Year: 2015 Prognostic factors in non-small cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016